Advisor Group’s Standard BioTools LAB Stock Holding History

Advisor Group’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$2K	Hold	600	–	–	﹤0.01%	4990
2019 Q3	$3K	Hold	600	–	–	﹤0.01%	4847
2019 Q2	$7K	Hold	600	–	–	﹤0.01%	4542
2019 Q1	$8K	Buy	+600	New	+$6.32K	﹤0.01%	4474
2018 Q1	–	Sell	-180	Closed	-$1K	–	5012
2017 Q4	$1K	Sell	180 -6,837	-97%	-$37.4K	﹤0.01%	4830
2017 Q3	$35K	Hold	7,017	–	–	﹤0.01%	3197
2017 Q2	$29K	Hold	7,017	–	–	﹤0.01%	3235
2017 Q1	$40K	Hold	7,017	–	–	﹤0.01%	2885
2016 Q4	$51K	Buy	7,017 +6,836	+3,777%	+$42.9K	﹤0.01%	2605
2016 Q3	$1K	Hold	181	–	–	﹤0.01%	4310
2016 Q2	$1K	Buy	+181	New	+$1.7K	﹤0.01%	4236

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Advisor Group's LAB Position: Q4 2019 in Review

Advisor Group held its Standard BioTools (LAB) position steady in Q4 2019 at 600 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4990.

Advisor Group first reported a position in LAB in Q2 2016 and has held it in 11 quarters since. The position peaked at $51K in Q4 2016. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2019.

Advisor Group held 600 shares of Standard BioTools worth $2K as of Q4 2019.
Advisor Group left its Standard BioTools share count unchanged in Q4 2019.
Standard BioTools made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4990 holding.
Advisor Group first reported a position in Standard BioTools in Q2 2016 and has held it in 11 quarters since.
Advisor Group's Standard BioTools position peaked at $51K in Q4 2016.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.